Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Chinese Biotech: Integrated R&D-Production-Sales vs. Specialized Division of Labor
-
JunHe LLP Session:New Models of Cross-Border Pharmaceutical Cooperation Session
-
Leveraging China Innovation to Accelerate Global Drug R&D Session
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Vaccine Innovation & Global Expansion Session
Stay tuned
Engine Reimagined: The mRNA Drug R&D Revolution Driven by AI and Automation
Ying Bo: Founder, Chairman and CEO, AbogenBio
The Breakthrough Direction for Pneumococcal Vaccines
Zhu Tao: Director and CSO, CanSino Biologics Inc.
AI-Enabled Innovation Incubation of Multivalent Combination Vaccines
Hou Jian: CEO, Xinzhi Biotech
Panel Discussion: China Vaccine Innovation and Global Expansion
Liao Xiang (Moderator): Director, Clover Biopharmaceuticals, Ltd.
Zhang Jiguo: President, Vaccine Business Unit, Fosun Pharma
Wu Hongbo: General Manager, Vaccine Business Unit, China National Biotec Group
Dong Shaozhong: Vice Chairman, Walvax Biotechnology Co., Ltd.
Meng Weining: Deputy General Manager and Head of International Business, Sinovac Biotech Ltd.
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
Stay tuned
【Session Curators】
Yan Zhang, Co-founder & Senior Vice President, MegaRobo
Xuan Xian, CIO & Director of AI Drug Research Institute, GeneScience Pharmaceutical
Opening Remarks
MegaRobo
Tian Qiong: Data Infrastructure for AI for Science
Zhixiang Ren, Chief AI Scientist, SmartLogic
De Novo Design and Development of Functional Antibodies Based on Generative Large Models
Shuangjia Zheng, Co-founder of Aureka, Researcher of Shanghai Jiao Tong University
Wet-lab Data Acquisition for Rapid Iteration of AI-powered Macromolecular Drugs
Lei Shi, SVP, Biointron
New Infrastructure for AI-driven Novel Drug R&D
Peifeng Tang, CTO, MegaRobo
How to Build an AI-native Biotech in One Year
Xuan Xian, CIO & Director of AI Drug Research Institute, GeneScience Pharmaceutical
TBD
Lianyi Han, Head of AIDD, Hengrui Medicine
TBD
Chris Lai, Co-founder, Chairman & CEO, METiS TechBio
Building an Ecosystem for AI-enabled Pharmaceutical R&D
Michael Fanjie, President, Pharmaceutical BU, Huawei
TBD
Yunlong Song, Founder & CEO, Yunji Zhiyao Biotechnology
Topic: AI-powered Pharmaceutical Era: Policy Guidance, Scenario Practice and Collaborative Evolution of Industrial Ecosystem
Yan Zhang(Moderator), Co-founder & Senior Vice President, MegaRobo
Xuan Xian, CIO & Director of AI Drug Research Institute, GeneScience Pharmaceutical
Huaxing Zhu, Chairman, Novoprotein
Zhiyong Xie, Chief AI Officer, Fosun Pharma
JunHe LLP Session:New Models of Cross-Border Pharmaceutical Cooperation Session
Stay tuned
Topic 1: Hurdles and Pitfalls in Overseas BD Transactions
Gerry Zhao：Partner, JunHe LLP
Topic 2: Legal Pain Points and Challenges of the Global Pharmaceutical Supply Chain
Frank Zhou：Partner, JunHe LLP
Topic 3: Where to List? Listing Strategy for Biotech & Pharma: STAR Market, HKEX, or US Stock Market?
Bella Chen：Partner, JunHe LLP
Nanobody Drug R&D Session
Stay tuned
Opening Remarks
Changchun Zha：Chairman, Biointron
Progress of Nanobody‑based Therapeutics & Applications in ADCs
Haikun Shi: Founder & Chairman, Kunyu Biotech
Development of Nanobody Therapeutics for Diabetic Nephropathy
Jiajun Fan: Director & Principal Investigator, Institute of Biotech Pharmaceuticals, Quzhou Fuda Biomedical Innovation Institute; Shanghai Rising Star Young Scientist
Dual-Epitope Nanobodies for Acute Disease Therapy Strategies
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma
Applications of Diverse Screening Platforms in Nanobody Discovery
Lei Shi: Senior Vice President, Biointron
Roundtable: Challenges and Future of Next‑Generation Antibody Drugs
Moderator: Haikun Shi: Founder & Chairman, Kunyu Biotech
Shuqing Chen: Professor & Doctoral Supervisor, College of Pharmaceutical Sciences, Zhejiang University; Founder & Chairman, Neoantigen
Jun Wang: General Manager,Jushi Biotech,CSPC Pharmaceutical Group
Tao Xu: Founder & CEO, SmartNuclide
Jing Huang: COO & CBO, Novamab
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma
CNS Novel Drug R&D Session
Stay tuned
Development of New Molecular Entity Drugs for Antipsychotic Indications
Tian Jingwei: Executive Vice President of R&D, Luye Pharma Group; Dean, School of Pharmacy, Yantai University
Medical Use and Market Prospects of Modified Psychedelics in Light of the FDA's New Guidance and Trump's Executive Order
Shen Huajiong: Founder & CEO, NeuShen Therapeutics
“PRODEGRE ATLAS – A Protein Degradation Innovation Platform to Enable Breakthrough Therapies for CNS Disorders”
Tan Shen: Co-Founder & CEO, Pridarray Biotech
Universal iPSC-Derived Cell Therapy for Brain Injury-Related Disorders
Fan Jing: Founder & CEO, Hopstem Biotechnology
Development of a Novel Small Molecule Drug for Stroke
Chen Rong: Deputy General Manager, Ningen Pharma
Development and Global Pathway of QP001 Injection
Yu Sen: VP, Qingpu Biopharma
Preliminary Validation of iPSC-Based Therapies for CNS Diseases Derived from the SISBAR Core Technology Platform
Wu Lanlin: CEO, Yuesai Biotechnology
Expanding the Extrabepatic Application of Small Nucleic Acid Drugs – R&D Progress in CNS Diseases
Gao Shan: Senior Vice President & Chief Scientist, Ribo Life Science
Research Progress of Cyclopolysaccharide Analog AMCDx Platform in CNS Diseases
Qi Youmao: Chairman, Aomu Pharma; Head of Academician Workstation; Chief Scientist
The Path to Clinical Translation of Innovative Biopharmaceuticals – Opportunities, Challenges, and Collaboration
Si Tianmei: Vice President, Peking University Sixth Hospital; Deputy Director, Institute of Mental Health
Frontier Technology in Innovative Drug Development
Isaac Cheng: VP of Research, Suntec Medical
Discovery and Development of a Novel Dual-Target, Non-Opioid Potent Analgesic
Sheng Xijun: Director, Innovation Research Center, Yichang Humanwell
Panel Discussion – The Future of CNS Drug R&D
Hei Yongjiang: Founder, Huisibo Biotech
Fang Qun: Chief Scientific Officer, Yisi Biotech; Head, Brain Science Innovation R&D Center
Li Qun: General Manager, Saipute
Wang Bingjie: CBO, Sunshine Angene Biotech
International Advanced Drug Delivery Systems & Combination Products
Stay tuned
Regulatory Administration of Combination Products in China
Senior Regulatory Expert
Frontiers of Combination Products
Zhen Gu: Assistant to the President, Zhejiang University; Director, State Key Laboratory of Advanced Drug Delivery Systems; Fellow, American Institute for Medical and Biological Engineering, International Academy for Medical and Biological Engineering, and Controlled Release Society
Development of Combination Products Amid the Boom of Large-Volume Subcutaneous Formulations
Liancheng Chen: CTO, ESC MEDICAL
Roundtable 1: Global Development of Combination Products
Lijie Zhang (Moderator): Founder, ESC MEDICAL
Zheng Wang: Co-founder & CEO, Shanghai Bao Pharmaceuticals Co., Ltd.
Quanmin Chen: Vice President, Formulation Development & Clinical Manufacturing, WuXi Biologics
Additional speakers to be announced...
Roundtable 2: R&D Priorities for Manufacturers and Service Providers in Drug-Device Collaboration
Hua Huang (Moderator): CEO, ESC MEDICAL
Yanhua Sun: Director, Peptide Drug Research Department, Qilu Pharmaceutical
Yingchun Li,Director, Biological Products Institute & Macromolecule CMC,R&D Institute, CHIA TAI Tianqing Pharmaceutical Group Co., Ltd.
Additional speakers to be announced...
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
